<\/p>\n
Alzheimer Derne\u011fi Uluslararas\u0131 Konferans\u0131’nda yay\u0131mlanan ara\u015ft\u0131rmaya g\u00f6re, \u0130sve\u00e7’te ara\u015ft\u0131rmac\u0131lar, 17 farkl\u0131 birinci basamak sa\u011fl\u0131k tesisinde kalan 307 orta ya\u015fl\u0131 ve ya\u015fl\u0131 hastan\u0131n verilerini inceledi.<\/p>\n
Bu kapsamda, ilk olarak doktorlar tam kapsaml\u0131 bir hastanede kat\u0131l\u0131mc\u0131lar\u0131 muayene ettikten sonra te\u015fhis koydu.<\/p>\n
\u0130kinci a\u015famada ise ara\u015ft\u0131rmac\u0131lar, Alzheimer hastalar\u0131n\u0131n beyninde bulunan “amyloid beta” proteini ve merkezi sinir sisteminde bulunan “tau” proteinine sahip olup olmad\u0131\u011f\u0131n\u0131 anlamak i\u00e7in kat\u0131l\u0131mc\u0131lardan kan \u00f6rne\u011fi istedi.<\/p>\n
Kat\u0131l\u0131mc\u0131lar, daha sonra haf\u0131zlar\u0131n\u0131n incelenmesi i\u00e7in kapsaml\u0131 klinik muayeneye tabi tutuldu.<\/p>\n
T\u00fcm incelemelerin sonunda doktorlar, kat\u0131l\u0131mc\u0131lar\u0131n yakla\u015f\u0131k y\u00fczde 55’inin Alzheimer ya da Alzheimer ili\u015fkili hastal\u0131\u011fa sahip oldu\u011funu saptarken, ikinci a\u015famada istenen kan tahlilinde doktor te\u015fhisine k\u0131yasla Alzheimer hastal\u0131\u011f\u0131 y\u00fczde 85 daha do\u011fru tespit edildi.<\/p>\n
Ara\u015ft\u0131rmada, s\u00f6z konusu kan testlerinin, Alzheimer’a daha h\u0131zl\u0131 ve do\u011fru te\u015fhis konulmas\u0131na yard\u0131mc\u0131 olabilece\u011fi tespit edildi.<\/p>\n
\u0130sve\u00e7 G\u00f6teborg \u00dcniversitesi Psikiyatri ve N\u00f6rokimya B\u00f6l\u00fcm\u00fc’nden Hanna Huber, diyabet hastalar\u0131n\u0131n d\u00fczenli olarak parmak ucu kan \u015fekeri \u00f6l\u00e7\u00fcm\u00fc yapmas\u0131 gibi Alzheimer hastal\u0131\u011f\u0131n\u0131n te\u015fhisi i\u00e7in de benzer kan testinin evde kolayca yap\u0131labilece\u011fini s\u00f6yledi.<\/p>\n
Huber, parmak ucundan al\u0131nan kan \u00f6rne\u011finin, hastal\u0131\u011f\u0131n erken te\u015fhisine yard\u0131mc\u0131 olmas\u0131n\u0131n yan\u0131 s\u0131ra hastal\u0131k s\u00fcrecinde de Alzheimer hastal\u0131\u011f\u0131n\u0131n ilerlemesinin daha iyi takip edilmesini sa\u011flayaca\u011f\u0131n\u0131 belirtti.<\/p>\n
\u0130sve\u00e7’teki Lund \u00dcniversitesinden ba\u015f ara\u015ft\u0131rmac\u0131 Sebastian Palmqvist de “Do\u011fru te\u015fhis ara\u00e7lar\u0131n\u0131n bulunmamas\u0131 nedeniyle, birinci basamak doktorlar\u0131n\u0131n bili\u015fsel bozuklu\u011fu olan hastalar aras\u0131nda bile Alzheimer hastal\u0131\u011f\u0131n\u0131 te\u015fhis etmesi, \u015fu anda \u00e7ok zor.” ifadesini kulland\u0131.<\/p>\n
Ara\u015ft\u0131rman\u0131n sonu\u00e7lar\u0131, Amsterdam’da d\u00fczenlenen Alzheimer Derne\u011fi Uluslararas\u0131 Konferans\u0131’nda yay\u0131mland\u0131.<\/p>\n
ABD G\u0131da ve \u0130la\u00e7 Dairesi (FDA), ocak ay\u0131nda \u00f6n onay\u0131 al\u0131nan, yeti\u015fkinlerde g\u00f6r\u00fclen Alzheimer hastal\u0131\u011f\u0131n\u0131n ilerlemesini yava\u015flatmaya y\u00f6nelik \u00fcretilen bir ilac\u0131 ilk kez tam onaylam\u0131\u015ft\u0131.<\/p>\n
Ara\u015ft\u0131rmalara g\u00f6re, 18 ayl\u0131k tedavi ile hastal\u0131\u011f\u0131n ilerlemesini y\u00fczde 27 yava\u015flatt\u0131\u011f\u0131 g\u00f6r\u00fclen ilac\u0131n, beyindeki amiloid-beta plaklar\u0131n\u0131 hedef ald\u0131\u011f\u0131 belirtiliyor.<\/p>\n
\u0130la\u00e7, haf\u0131za ve d\u00fc\u015f\u00fcnmedeki zay\u0131flamay\u0131 yava\u015flatabilece\u011fini ortaya koyan, t\u00fcr\u00fcn\u00fcn ilk \u00f6rne\u011fi olarak g\u00f6steriliyor. Piyasadaki di\u011fer ila\u00e7lar hastal\u0131\u011f\u0131n yaln\u0131zca semptomlar\u0131n\u0131 hedef al\u0131yordu.<\/p>\n